The first dosage of its plasmid DNA vaccine ZyCoV-D was administered to a human test subject on Wednesday, the company said in a statement.
The company said the DNA vaccine platform it had developed could be used to modify the vaccine in a couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: